急性缺血性卒中与脑出血患者的利伐沙班血浆水平
这项多中心注册研究比较了241例服用利伐沙班期间发生卒中患者的利伐沙班血浆水平,其中190例急性缺血性卒中、51例脑出血。两组利伐沙班血浆水平相似;56.8%的缺血性卒中患者利伐沙班血浆水平≤100ng/ml,可能适合溶栓;64.7%的脑出血患者利伐沙班血浆水平≥75ng/ml,可能符合特异性逆转剂使用条件。国际标准化比值阈值在个体患者治疗决策中表现不佳。
要点
- 急性缺血性卒中与脑出血患者的利伐沙班血浆水平相似(82ng/ml vs 102ng/ml,p=0.24)。
- 56.8%的急性缺血性卒中患者利伐沙班血浆水平≤100ng/ml,可能适合溶栓。
- 64.7%的脑出血患者利伐沙班血浆水平≥75ng/ml,可能符合特异性逆转剂使用条件。
核心结论
- 急性缺血性卒中与脑出血患者的利伐沙班血浆水平无差异。
- 约半数服用利伐沙班的急性缺血性卒中患者利伐沙班血浆水平低至可考虑溶栓。
- 约三分之二的脑出血患者利伐沙班血浆水平高至符合特异性逆转剂使用条件。
- 国际标准化比值阈值在个体患者治疗决策中表现不佳。
研究设计与样本
- 多中心注册研究(新型口服抗凝药卒中患者协作;ClinicalTrials.gov:NCT02353585),纳入服用利伐沙班期间发生卒中的患者,比较急性缺血性卒中与脑出血患者的利伐沙班血浆水平。
- 共241例患者,中位年龄80岁(四分位距73-84),中位发病至入院时间2小时(四分位距1-4.5小时),中位利伐沙班血浆水平89ng/ml(四分位距31-194)。
- 其中急性缺血性卒中190例,脑出血51例。
主要发现
- 利伐沙班血浆水平在急性缺血性卒中患者为82ng/ml(四分位距30-202),在脑出血患者为102ng/ml(四分位距51-165),两组相似(p=0.24)。
- 谷浓度利伐沙班血浆水平(≤137ng/ml)见于急性缺血性卒中126/190例(66.3%)和脑出血34/51例(66.7%)。
- 急性缺血性卒中患者中108/190例(56.8%)利伐沙班血浆水平≤100ng/ml;脑出血患者中33/51例(64.7%)利伐沙班血浆水平≥75ng/ml。
- 利伐沙班血浆水平与利伐沙班剂量相关,与肾功能和距末次服药时间呈负相关(各p<0.05)。
- 国际标准化比值≤1.0预测利伐沙班血浆水平≤100ng/ml的特异性为98.9%、敏感性为25.7%;国际标准化比值≥1.4预测利伐沙班血浆水平≥75ng/ml的敏感性为59.3%、特异性为90.1%。
关键数值与推荐
- 急性缺血性卒中患者利伐沙班血浆水平≤100ng/ml提示可能适合溶栓,190例中108例(56.8%)符合。
- 脑出血患者利伐沙班血浆水平≥75ng/ml提示可能符合特异性逆转剂使用条件,51例中33例(64.7%)符合。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. METHODS: In a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev ≤ 100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev ≥ 75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. RESULTS: Among 241 patients (median age = 80 years, interquartile range [IQR] = 73-84; median time from onset to admission = 2 hours, IQR = 1-4.5 hours; median RivLev = 89ng/ml, IQR = 31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR = 30-202) and ICH patients (102ng/ml, IQR = 51-165; p = 0.24). Trough RivLev(≤137ng/ml) occurred in 126/190 (66.3%) AIS and 34/51 (66.7%) ICH patients. Among AIS patients, 108/190 (56.8%) had RivLev ≤ 100ng/ml. In ICH patients, 33/51 (64.7%) had RivLev ≥ 75ng/ml. RivLev was associated with rivaroxaban dosage, and inversely with renal function and time since last intake (each p < 0.05). INR ≤ 1.0 had a specificity of 98.9% and a sensitivity of 25.7% to predict RivLev ≤ 100ng/ml. INR ≥ 1.4 had a sensitivity of 59.3% and specificity of 90.1% to predict RivLev ≥ 75ng/ml. INTERPRETATION: RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459.
引用
- Seiffge DJ, Kägi G, Michel P, et al. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol. 2018. PMID: 29394504. doi:10.1002/ana.25165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。